Former GSK cancer R&D chief Paoletti takes the reins at GammaDelta; Blueprint inks big Cambridge lease

Paolo Paoletti, the former president of GSK’s oncology R&D group, has taken the helm at Abingworth-backed GammaDelta Therapeutics. “I’m extremely excited to take on this role to further advance the pioneering research on gamma delta (γδ) T cells of the company’s founders, Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute,” Paoletti said in a statement. “The unique properties of γδ T cells, coupled with the proprietary knowledge of the company offer great prospects for the development of innovative immunotherapies for many forms of cancers, including solid tumours, and potentially auto-inflammatory diseases.” Pfizer vet Natalie Mount joined the biotech as CSO.

Blueprint CEO Jeff Albers has inked a new lease for 100,000 square feet in Cambridge, MA, according to the Boston Business Journal.

NewLink $NLNK says that it has “a next-generation compound, a novel prodrug of indoximod, NLG802, which we expect to enter the clinic by the end of Q3 this year.”

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy

EvaluatePharma World Preview 2017